文献速递前列腺癌

基于Gleason升级风险的低危前列腺癌主动监测个体化活检方案

Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance.
PubMed 文献 · BJU Int · 2020-08-01

模型在验证队列中AUC为0.6-0.7,PSA速度较PSA水平预测力更强(HR 2.47 vs 0.99)。基于风险的个体化活检方案可减少不必要活检并维持肿瘤控制,已实现为网页应用。

要点

  • 基于PSA速度与水平的贝叶斯模型可预测主动监测中的Gleason升级风险。
  • 个体化活检方案依据升级风险阈值触发,替代固定年度活检。
  • 模型已完成外部验证并实现为网页应用,支持共享决策。

核心结论

  • 成功开发并验证了预测Gleason升级风险的模型,提供基于风险的个体化活检决策,可能减少不必要活检同时维持肿瘤控制。

研究设计与样本

  • 基于PRIAS研究(7813例,1134例升级)的重复PSA、既往活检时机与结果及基线年龄数据,拟合贝叶斯联合模型(时间-事件与纵向数据)。

主要发现

  • PRIAS队列5年随访时Cause-specific累积升级风险为35%,GAP3队列中最高达50%。
  • PRIAS模型中PSA速度对升级的预测强度(HR 2.47,95%CI 1.93-2.99)高于PSA水平(HR 0.99,95%CI 0.89-1.11)。
  • 模型在验证队列中AUC为0.6-0.7;在PSA水平与速度影响与PRIAS相似的GAP3队列中预测误差为0.1-0.2,否则为0.2-0.3。
  • 验证队列中模型需重新校准基线升级风险。

关键数值与推荐

  • 当患者预测升级风险超过某一阈值时安排活检,阈值由患者/医生共享决策选择。
  • 为每个方案提供计划活检的时间与总次数(负担)以及检测升级的预期时间延迟(越短越好)。
  • 网页应用(http://tiny.cc/biopsy)实现验证模型与个体化方案,比较固定与个体化方案的总活检次数和预期时间延迟。

临床怎么用

  • 临床医生可利用网页应用输入患者PSA动态、既往活检结果和年龄,获取个体化升级风险预测。
  • 通过比较不同活检方案的总活检次数与检测升级的时间延迟,辅助医患共享决策。
  • 个体化方案可作为固定年度活检的替代,以减少不必要的前列腺活检。

局限性

  • 模型在部分验证队列中预测误差较大(0.2-0.3),需重新校准基线升级风险。
  • AUC仅为0.6-0.7,区分度中等。
  • 研究基于PRIAS和GAP3队列,外推至其他人群需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop a model and methodology for predicting the risk of Gleason upgrading in patients with prostate cancer on active surveillance (AS) and using the predicted risks to create risk-based personalised biopsy schedules as an alternative to one-size-fits-all schedules (e.g. annually). Furthermore, to assist patients and doctors in making shared decisions on biopsy schedules, by providing them quantitative estimates of the burden and benefit of opting for personalised vs any other schedule in AS. Lastly, to externally validate our model and implement it along with personalised schedules in a ready to use web-application. PATIENTS AND METHODS: Repeat prostate-specific antigen (PSA) measurements, timing and results of previous biopsies, and age at baseline from the world's largest AS study, Prostate Cancer Research International Active Surveillance (PRIAS; 7813 patients, 1134 experienced upgrading). We fitted a Bayesian joint model for time-to-event and longitudinal data to this dataset. We then validated our model externally in the largest six AS cohorts of the Movember Foundation's third Global Action Plan (GAP3) database (>20 000 patients, 27 centres worldwide). Using the model predicted upgrading risks; we scheduled biopsies whenever a patient's upgrading risk was above a certain threshold. To assist patients/doctors in the choice of this threshold, and to compare the resulting personalised schedule with currently practiced schedules, along with the timing and the total number of biopsies (burden) planned, for each schedule we provided them with the time delay expected in detecting upgrading (shorter is better). RESULTS: The cause-specific cumulative upgrading risk at the 5-year follow-up was 35% in PRIAS, and at most 50% in the GAP3 cohorts. In the PRIAS-based model, PSA velocity was a stronger predictor of upgrading (hazard ratio [HR] 2.47, 95% confidence interval [CI] 1.93-2.99) than the PSA level (HR 0.99, 95% CI 0.89-1.11). Our model had a moderate area under the receiver operating characteristic curve (0.6-0.7) in the validation cohorts. The prediction error was moderate (0.1-0.2) in theGAP3 cohorts where the impact of the PSA level and velocity on upgrading risk was similar to PRIAS, but large (0.2-0.3) otherwise. Our model required re-calibration of baseline upgrading risk in the validation cohorts. We implemented the validated models and the methodology for personalised schedules in a web-application (http://tiny.cc/biopsy). CONCLUSIONS: We successfully developed and validated a model for predicting upgrading risk, and providing risk-based personalised biopsy decisions in AS of prostate cancer. Personalised prostate biopsies are a novel alternative to fixed one-size-fits-all schedules, which may help to reduce unnecessary prostate biopsies, while maintaining cancer control. The model and schedules made available via a web-application enable shared decision-making on biopsy schedules by comparing fixed and personalised schedules on total biopsies and expected time delay in detecting upgrading.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Tomer A, Nieboer D, Roobol MJ, et al. Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. BJU Int. 2020. PMID: 32531869. doi:10.1111/bju.15136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。